Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06951217 · ClinicalTrials.gov registry record · Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis, sponsored by Avalyn Pharma.

Recruiting
Registry status
Phase 2
Development phase
340
Enrollment target
20
Study locations

NCT06951217 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by Avalyn Pharma. The registered enrollment target is 340 participants, below the 454-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06951217, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by Avalyn Pharma.

RECRUITING
Registry status
Phase 2
Development phase
340 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.

Conditions Studied

Idiopathic Pulmonary Fibrosis (IPF) Progressive Pulmonary Fibrosis

Interventions

  • COMBINATION_PRODUCT AP01

Study Locations (20)

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University - New York

North Carolina

  • Piedmont HealthCare, PA - Statesville
  • Southeastern Research Center - Winston-Salem

Ohio

  • University of Cincinnati - Cincinnati
  • The University of Kansas Medical Center - Kansas

Pennsylvania

  • Thomas Jefferson University - Philadelphia
  • Temple University Hospital - Philadelphia

South Carolina

  • Lowcountry Lung and Critical Care, PA - Charleston
  • Medical University of South Carolina - Charleston

Colorado

  • University of Colorado, Anschutz Medical Campus - Aurora

Florida

  • Renstar Medical Research - Ocala

Georgia

  • Piedmont Healthcare, Inc. - Atlanta

Trial Details

FieldValue
Enrollment Target 340 participants
Start Date 2025-04-17
Est. Completion 2031-12-31
Phase Phase 2

Sponsor

Avalyn Pharma

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06951217

The ClinicalTrials.gov registry entry for NCT06951217 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (25% lower). The listed sponsor is Avalyn Pharma, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 1 intervention - of which AP01 is the first listed.

NCT06951217 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, North Carolina, Ohio.

Frequently Asked Questions

What is clinical trial NCT06951217 about?

NCT06951217 is a clinical study titled "An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)". This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE...

What is the current status of trial NCT06951217?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2025-04-17. Estimated completion is 2031-12-31.

What conditions does trial NCT06951217 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis.

What interventions are being tested in trial NCT06951217?

The interventions under investigation include: AP01 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06951217?

This trial is sponsored by Avalyn Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06951217 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis (IPF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis (IPF)

All registered trials for this condition

Progressive Pulmonary Fibrosis

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.